Fennec Pharmaceuticals Inc. (FENC)
After hours:
| Previous Close | 7.12 |
| Open | 7.03 |
| Bid | 6.99 x 100 |
| Ask | 7.07 x 200 |
| Day's Range | 6.70 - 7.09 |
| 52 Week Range | 6.30 - 11.92 |
| Volume | |
| Avg. Volume | 161,861 |
| Market Cap | 192.313M |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 176.00 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~ ~ Amended PEDMARK Permanent J-code 07901 Became Effective April 1, 2024 ~ ~ Company Has Approximately $51 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30
- GlobeNewswire
Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024
RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Tuesday, May
- GlobeNewswire
Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update
~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI™ in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and Regulatory Milestones, and Tiered Royalties Up to the Mid-Twenties ~ ~ Pro forma fourth quarter cash in excess of $55 million ~ ~ Managemen
